조현병 연구를 위한 동물 행동 실험

키워드

참고문헌 (122)

1. Tamminga CA, "The neurobiology of cognition in schizophrenia", J Clin Psychiatry, 67(Suppl 9), pp.9~13 (2006)
2. Lipska BK, "To model a psychiatric disorder in animals: schizophrenia as a reality test", Neuropsychopharmacology, 23, pp.223~239 (2000)
3. Lahti AC, "Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers", Neuropsychopharmacology, 25, pp.455~467 (2001)
4. Tamminga CA, "Phenotype of schizophrenia: a re-view and formulation", Mol Psychiatry, 10, pp.27~39 (2005)
5. Carpenter WT Jr, "Deficit and non-deficit forms of schizophrenia: the concept", Am J Psychiatry, 145, pp.578~583 (1988)
6. Planansky K, "Depressive syndrome in schizophrenia", Acta Psychiatr Scand, 57, pp.207~218 (1978)
7. Goodwin RD, "Anxiety and substance use comorbidity among in-patients with schizophrenia", Schizophr Res, 61, pp.89~95 (2003)
8. Chapman J, "The early symptoms of schizophrenia", Br J Psychiatry, 112, pp.225~251 (1966)
9. Kuroda K, "Behavioral alterations associated with targeted disruption of exons 2 and 3 of the Disc1 gene in the mouse", Hum Mol Genet, 20, pp.4666~4683 (2011)
10. Elvevag B, "Cognitive impairment in schizophrenia is the core of the disorder", Crit Rev Neurobiol, 14, pp.1~21 (2000)
11. Hoff AL, "Familial cognitive deficits in schizophrenia", Am J Med Genet B Neuropsychiatr Genet, 133B, pp.43~49 (2005)
12. Ranganath C, "The cognitive neuro-science of memory function and dysfunction in schizophrenia", Biol Psychiatry, 64, pp.18~25 (2008)
13. Henry JD, "A meta-analytic review of verbal fluency deficits in schizophrenia relative to other neurocognitive deficits", Cogn Neuropsychiatry, 10, pp.1~33 (2005)
14. Barch DM, "The cognitive neuroscience of working mem-ory: relevance to CNTRICS and schizophrenia", Biol Psychiatry, 64, pp.11~17 (2008)
15. Saykin AJ, "Neuropsychological function in schizophrenia. Selec-tive impairment in memory and learning", Arch Gen Psychiatry, 48, pp.618~624 (1991)
16. Moghaddam B, "Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats", Science, 281, pp.1349~1352 (1998)
17. Lubow RE, "Construct validity of the animal latent inhibition model of selective attention deficits in schizophrenia", Schizophr Bull, 31, pp.139~153 (2005)
18. Miyakawa T, "Conditional calcineurin knockout mice exhib-it multiple abnormal behaviors related to schizophrenia", Proc Natl Acad Sci U S A, 100, pp.8987~8992 (2003)
19. Braff DL, "Sensorimotor gating and schizophrenia. Hu-man and animal model studies", Arch Gen Psychiatry, 47, pp.181~188 (1990)
20. Lodge DJ, "Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophre-nia", Behav Brain Res, 204, pp.306~312 (2009)
21. Hradetzky E, "The methylazoxymethanol acetate (MAM-E17) rat model: molecular and functional effects in the hippocam-pus", Neuropsychopharmacology, 37, pp.364~377 (2012)
22. Jones CA, "Animal models of schizophrenia", Br J Pharmacol, 164, pp.1162~1194 (2011)
23. Kapur S, "NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D and serotonin 5-HT-receptors-implications for models of schizophrenia", Mol Psychi-atry, 7, pp.837~844 (2002)
24. Egerton A, "Impair-ment in perceptual attentional set-shifting following PCP admin-istration: a rodent model of set-shifting deficits in schizophrenia", Psychopharmacology (Berl), 179, pp.77~84 (2005)
25. Sams-Dodd F, "Distinct effects of d-amphetamine and phencycli-dine on the social behaviour of rats", Behav Pharmacol, 6, pp.55~65 (1995)
26. Kalinichev M, "Comparison between intraperitoneal and sub-cutaneous phencyclidine administration in Sprague-Dawley rats:a locomotor activity and gene induction study", Prog Neuropsy-chopharmacol Biol Psychiatry, 32, pp.414~422 (2008)
27. Mansbach RS, "Effects of phencyclidine and phency-clidine biologs on sensorimotor gating in the rat", Neuropsycho-pharmacology, 2, pp.299~308 (1989)
28. Sams-Dodd F, "A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine", Neu-ropsychopharmacology, 18, pp.293~304 (1998)
29. Phillips M, "Pharmacological characteriza-tion of locomotor sensitization induced by chronic phencyclidine administration", J Pharmacol Exp Ther, 296, pp.905~913 (2001)
30. Berman S, "Abuse of amphetamines and structural abnormalities in the brain", Ann N Y Acad Sci, 1141, pp.195~220 (2008)
31. Fletcher PJ, "A sensitizing regimen of amphetamine impairs visual attention in the 5-choice serial reaction time test: reversal by a D1 receptor agonist injected into the medial prefrontal cortex", Neuropsychopharmacology, 32, pp.1122~1132 (2007)
32. Featherstone RE, "A sensitizing regimen of amphetamine that disrupts attentional set-shifting does not disrupt working or long-term memory", Behav Brain Res, 189, pp.170~179 (2008)
33. Peleg-Raibstein D, "Withdrawal from repeated amphetamine administration leads to disruption of prepulse inhibition but not to disruption of latent inhibition", J Neural Transm, 113, pp.1323~1336 (2006)
34. Fletcher PJ, "Sensitization to amphetamine, but not PCP, impairs attentional set shifting: rever-sal by a D1 receptor agonist injected into the medial prefrontal cortex", Psychopharmacology (Berl), 183, pp.190~200 (2005)
35. Tenn CC, "Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibi-tion", Psychopharmacology (Berl), 180, pp.366~376 (2005)
36. Ayhan Y, "Animal models of gene-environment interactions in schizophrenia", Behav Brain Res, 204, pp.274~281 (2009)
37. Harrison PJ, "Schizophrenia genes, gene expres-sion, and neuropathology: on the matter of their convergence", Mol Psychiatry, 10, pp.40~68 (2005)
38. Gogos JA, "Schizophrenia susceptibility genes: emer-gence of positional candidates and future directions", Trends Phar-macol Sci, 27, pp.226~233 (2006)
39. International Schizophrenia C, "Rare chromosomal deletions and duplications increase risk of schizophrenia", Nature, 455, pp.237~241 (2008)
40. Stefansson H, "Large recurrent microdeletions associated with schizophrenia", Nature, 455, pp.232~236 (2008)
41. Walsh T, "Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia", Science, 320, pp.539~543 (2008)
42. Millar JK, "Disruption of two novel genes by a translocation co-segregating with schizophrenia", Hum Mol Genet, 9, pp.1415~1423 (2000)
43. Jaaro-Peled H, "Gene models of schizophrenia: DISC1 mouse mod-els", Prog Brain Res, 179, pp.75~86 (2009)
44. Hikida T, "Dominant-negative DISC1 transgenic mice display schizo-phrenia-associated phenotypes detected by measures translatable to humans", Proc Natl Acad Sci U S A, 104, pp.14501~14506 (2007)
45. Shen S, "Schizo-phrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated Disc1", J Neurosci, 28, pp.10893~10904 (2008)
46. Clapcote SJ, "Behavioral phenotypes of Disc1 missense mutations in mice", Neuron, 54, pp.387~402 (2007)
47. Pletnikov MV, "Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia", Mol Psychiatry, 13, pp.173~186 (2008)
48. Li W, "Specific developmental disruption of disrupted-in-schizophrenia-1function results in schizophrenia-related phenotypes in mice", Proc Natl Acad Sci U S A, 104, pp.18280~18285 (2007)
49. Desbonnet L, "Mutant models for genes associated with schizophrenia", Biochem Soc Trans, 37(Pt 1), pp.308~312 (2009)
50. Law AJ, "Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5’ SNPs associated with the disease", Proc Natl Acad Sci U S A, 103, pp.6747~6752 (2006)
51. Mei L, "Neuregulin 1 in neural development, synaptic plasticity and schizophrenia", Nat Rev Neurosci, 9, pp.437~452 (2008)
52. Gerlai R, "Heregulin, but not ErbB2 or ErbB3, heterozygous mutant mice exhibit hyperactivity in multiple be-havioral tasks", Behav Brain Res, 109, pp.219~227 (2000)
53. Stefansson H, "Common variants conferring risk of schizo-phrenia", Nature, 460, pp.744~747 (2009)
54. Harrison PJ, "Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology", Biol Psychiatry, 60, pp.132~140 (2006)
55. Talbot K, "The sandy (sdy) mouse: a dysbindin-1 mutant relevant to schizophrenia research", Prog Brain Res, 179, pp.87~94 (2009)
56. Schwab SG, "Support for association of schizo-phrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families", Am J Hum Genet, 72, pp.185~190 (2003)
57. Morris DW, "Dysbindin (DTNBP1) and the biogenesis of lysosome-related organelles complex 1 (BLOC-1): main and epi-static gene effects are potential contributors to schizophrenia sus-ceptibility", Biol Psychiatry, 63, pp.24~31 (2008)
58. Straub RE, "Genetic variation in the 6p22.3 gene DTNBP1, the hu-man ortholog of the mouse dysbindin gene, is associated with schizophrenia", Am J Hum Genet, 71, pp.337~348 (2002)
59. Talbot K, "Dysbindin-1 is reduced in intrinsic, glutamater-gic terminals of the hippocampal formation in schizophrenia", J Clin Invest, 113, pp.1353~1363 (2004)
60. Tang J, "Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cas-es is reduced in an isoform-specific manner unrelated to dysbin-din-1 mRNA expression", Hum Mol Genet, 18, pp.3851~3863 (2009)
61. Weickert CS, "Human dysbindin (DTNBP1) gene ex-pression in normal brain and in schizophrenic prefrontal cortex and midbrain", Arch Gen Psychiatry, 61, pp.544~555 (2004)
62. Weickert CS, "Reduced DTNBP1 (dysbindin-1) mRNA in the hippocampal for-mation of schizophrenia patients", Schizophr Res, 98, pp.105~110 (2008)
63. Iizuka Y, "Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor in-ternalization and signaling but not D1 internalization", J Neurosci, 27, pp.12390~12395 (2007)
64. Ji Y, "Role of dysbindin in dopamine receptor trafficking and cortical GABA function", Proc Natl Acad Sci U S A, 106, pp.19593~19598 (2009)
65. Dickman DK, "The schizophrenia susceptibility gene dysbindin controls synaptic homeostasis", Science, 326, pp.1127~1130 (2009)
66. Jenzsch A, "Nutrition-al intervention in patients with periodontal disease: clinical, im-munological and microbiological variables during 12 months", Br J Nutr, 101, pp.879~885 (2009)
67. Papaleo E, "Molecular dynamics investigation of cyclic natriuretic peptides:dynamic properties reflect peptide activity", J Mol Graph Model, 28, pp.34~841 (2010)
68. Karlsgodt KH, "Reduced dysbindin expression mediates N-methyl-D-aspartate receptor hypofunction and impaired working memory performance", Biol Psychiatry, 69, pp.28~34 (2011)
69. Papaleo F, "Dys-bindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine", D2 pathways, 2012, pp.17, 85~98
70. Cassidy AW, "Developmental emergence of reelin deficits in the prefrontal cortex of Wistar rats reared in social isolation", Neuroscience, 166, pp.377~385 (2010)
71. Liu Y, "Replication of an association of a common variant in the Reelin gene (RELN) with schizophrenia in Ashkenazi Jewish women", Psychiatr Genet, 20, pp.184~186 (2010)
72. Wedenoja J, "Replication of association between working memory and Reelin, a potential modifier gene in schizophrenia", Biol Psychiatry, 67, pp.983~991 (2010)
73. Guidotti A, "Decrease in reelin and glutamic acid decarbox-ylase67 (GAD67) expression in schizophrenia and bipolar disor-der: a postmortem brain study", Arch Gen Psychiatry, 57, pp.1061~1069 (2000)
74. Impagnatiello F, "A decrease of reelin expression as a putative vul-nerability factor in schizophrenia", Proc Natl Acad Sci U S A, 95, pp.15718~15723 (1998)
75. Bellon A, "Potential ap-plication as screening and drug designing tools of cytoarchitec-tural deficiencies present in three animal models of schizophrenia", Expert Opin Drug Discov, 4, pp.257~278 (2009)
76. O’Tuathaigh CM, "Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia", Schizophr Bull, 36, pp.271~288 (2010)
77. Tueting P, "Reelin down-regulation in mice and psychosis endophenotypes", Neuro-sci Biobehav Rev, 30, pp.1065~1077 (2006)
78. Krueger DD, "Assessment of cognitive function in the heterozygous reeler mouse", Psychopharmacology (Berl), 189, pp.95~104 (2006)
79. Fatemi SH, "Prenatal viral infection leads to pyramidal cell atrophy and macrocephaly in adulthood: implications for genesis of au-tism and schizophrenia", Cell Mol Neurobiol, 22, pp.25~33 (2002)
80. Fatemi SH, "Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelopmental disorders", Schizophr Res, 99, pp.56~70 (2008)
81. Vyas A, "Be-havioral changes induced by Toxoplasma infection of rodents are highly specific to aversion of cat odors", Proc Natl Acad Sci U S A, 104, pp.6442~6447 (2007)
82. Nyffeler M, "Maternal im-mune activation during pregnancy increases limbic GABAA re-ceptor immunoreactivity in the adult offspring: implications for schizophrenia", Neuroscience, 143, pp.51~62 (2006)
83. Makinodan M, "Maternal immune activation in mice delays myelination and axonal development in the hippocampus of the offspring", J Neurosci Res, 86, pp.2190~2200 (2008)
84. Baharnoori M, "Prenatal immune chal-lenge induces developmental changes in the morphology of py-ramidal neurons of the prefrontal cortex and hippocampus in rats", Schizophr Res, 107, pp.99~109 (2009)
85. Miyazaki S, "In-traperitoneal injection of lipopolysaccharide induces dynamic mi-gration of Gr-1high polymorphonuclear neutrophils in the murine abdominal cavity", Clin Diagn Lab Immunol, 11, pp.452~457 (2004)
86. Nogai A, "Lipopolysaccharide injection induces relaps-es of experimental autoimmune encephalomyelitis in nontrans-genic mice via bystander activation of autoreactive CD4+ cells", J Immunol, 175, pp.959~966 (2005)
87. Meyer U, "To poly (I:C) or not to poly (I:C): advancing preclinical schizophrenia research through the use of prenatal im-mune activation models", Neuropharmacology, 62, pp.1308~1321 (2012)
88. Silva-Gomez AB, "Decreased dendritic spine density on prefrontal cortical and hippocampal pyramidal neurons in postweaning social isolation rats", Brain Res, 983, pp.128~136 (2003)
89. Day-Wilson KM, "Me-dial prefrontal cortex volume loss in rats with isolation rearing-in-duced deficits in prepulse inhibition of acoustic startle", Neurosci-ence, 141, pp.1113~1121 (2006)
90. Fone KC, "Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmen-tal neuropsychiatric disorders", Neurosci Biobehav Rev, 32, pp.1087~1102 (2008)
91. Niwa M, "Vulner-ability in early life to changes in the rearing environment plays a crucial role in the aetiopathology of psychiatric disorders", Int J Neuropsychopharmacol, 14, pp.459~477 (2011)
92. Pascual R, "Effects of postwean-ing social isolation and re-socialization on the expression of va-soactive intestinal peptide (VIP) and dendritic development in the medial prefrontal cortex of the rat", Acta Neurobiol Exp (Wars), 66, pp.7~14 (2006)
93. Marsden CA, "Influence of social isolation in the rat on serotonergic function and memory--relevance to models of schizophrenia and the role of 5-HT receptors", Neuropharma-cology, 61, pp.400~407 (2011)
94. McLean S, "Isolation rearing impairs novel object recognition and attentional set shifting performance in female rats", J Psychopharmacol, 24, pp.57~63 (2010)
95. King MV, "Increased dopamine D2High receptors in rats reared in social isolation", Synapse, 63, pp.476~483 (2009)
96. Bianchi M, "Isolation rearing induces recognition memory deficits accom-panied by cytoskeletal alterations in rat hippocampus", Eur J Neu-rosci, 24, pp.2894~2902 (2006)
97. Schubert MI, "Ef-fects of social isolation rearing on the limbic brain: a combined behavioral and magnetic resonance imaging volumetry study in rats", Neuroscience, 159, pp.21~30 (2009)
98. Cash-Padgett T, "DISC1 mouse models as a tool to decipher gene-environment interactions in psychiatric disorders", Front Behav Neurosci, 7, pp.113~ (2013)
99. Kudryavtseva NN, "Social model of depression in mice of C57BL", 6J strain, 1991, pp.38, 315~320
100. Venzala E, "Chronic social defeat stress model: behavioral features, anti-depressant action, and interaction with biological risk factors", Psy-chopharmacology (Berl), 224, pp.313~325 (2012)
101. Kannan G, "Mouse models of gene-envi-ronment interactions in schizophrenia", Neurobiol Dis, 57, pp.5~11 (2013)
102. Niwa M, "Adolescent stress-induced epigenetic control of do-paminergic neurons via glucocorticoids", Science, 339, pp.335~339 (2013)
103. Caspi A, "Gene-environment interactions in psychiatry:joining forces with neuroscience", Nat Rev Neurosci, 7, pp.583~590 (2006)
104. Rutter M, "Gene-environment interplay and psychopathology: multiple varieties but real effects", J Child Psy-chol Psychiatry, 47, pp.226~261 (2006)
105. Rutter M, "Biological implications of gene-environment interac-tion", J Abnorm Child Psychol, 36, pp.969~975 (2008)
106. Denenberg VH, "Open-field bheavior in the rat: what does it mean?", Ann N Y Acad Sci, 159, pp.852~859 (1969)
107. File SE, "Can social interaction be used to measure anxi-ety?", Br J Pharmacol, 62, pp.19~24 (1978)
108. Sams-Dodd F, "Automation of the social interaction test by a video-tracking system: behavioural effects of repeated phencyclidine treatment", J Neurosci Methods, 59, pp.157~167 (1995)
109. Nadler JJ, "Automated apparatus for quantitation of social approach behav-iors in mice", Genes Brain Behav, 3, pp.303~314 (2004)
110. Braff DL, "Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharma-cological studies", Psychopharmacology (Berl), 156, pp.234~258 (2001)
111. Swerdlow NR, "Realistic ex-pectations of prepulse inhibition in translational models for schizo-phrenia research", wPsychopharmacology (Berl), 199, pp.331~388
112. Kim JJ, "Modality-specific retrograde amnesia of fear", Science, 256, pp.675~677 (1992)
113. Fanselow MS, "The neuroscience of mammalian asso-ciative learning", Annu Rev Psychol, 56, pp.207~234 (2005)
114. Morris R, "Developments of a water-maze procedure for studying spatial learning in the rat", J Neurosci Methods, 11, pp.47~60 (1984)
115. D’Hooge R, "Applications of the Morris water maze in the study of learning and memory", Brain Res Brain Res Rev, 36, pp.60~90 (2001)
116. Freeman JH Jr, "Fimbria-fornix transections disrupt the ontogeny of delayed alternation but not position discrimina-tion in the rat", Behav Neurosci, pp.386~395 (1991)
117. Robbins TW, "The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry", Psychopharmacol-ogy (Berl), 163, pp.362~380 (2002)
118. Bari A, "The application of the 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats", Nat Protoc, 3, pp.759~767 (2008)
119. Monchi O, "Wisconsin Card Sorting revisited: distinct neural circuits participating in different stages of the task identified by event-related functional magnetic resonance imaging", J Neurosci, pp.7733~7741 (2001)
120. Birrell JM, "Medial frontal cortex mediates perceptual attentional set shifting in the rat", J Neurosci, 20, pp.4320~4324 (2000)
121. Colacicco G, "Attentional set-shifting in mice: modification of a rat paradigm, and evidence for strain-dependent variation", Behav Brain Res, 132, pp.95~102 (2002)
122. Swerdlow NR, "Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and fu-ture challenges", Psychopharmacology (Berl), 156, pp.194~215 (2001)

관련 논문AI추천